BTX: BioTime, Inc Instablogs

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, June 4, 12:45 PM Midday top 10 gainers: ET +53%. NURO +47%. INFI +20%. GIII +18%. OIBR +18%. IFMI +12%. MHGC +13%. WPCS +13%. BEAT +12%. AMPE +12%. Midday top 10 Losers: FBN -19%. RIGL -18%. LPHI -13%. PSTI -14%. GIG -10%. BTX -10%. OSH -10%. VRML -10%. ENTA -9%. ZLC -10%. Comment!
Thursday, May 23, 1:48 PM BioTime (BTX -0.2%) says its shareholders have overwhelmingly approved the planned acquisition of stem cell-related assets from Geron (GERN). The green light was given at a special meeting of shareholders, with at least 32.5M votes coming in favor from the 34.5M shares represented and voted. Comment! [Healthcare, M&A]
Friday, April 19, 9:43 AM BioTime (BTX +4.7%) moves higher after announcing an exclusive licensing agreement with UCLA for the company's HyStem hydrogels which "deliver locally released growth factors to improve recovery from stroke." The company hopes the related research (performed by Dr. Tom Carmichael) will pave the way for an investigational new drug application with the FDA. Comment! [Healthcare, On the Move]
Tuesday, March 19, 12:51 PM BioTime (BTX -7.6%) takes a hit today after reporting late Monday a Q4 loss of $0.12 per share, compared with a loss of $0.11 per share in the same period last year. Revenues were $1.22M, also down from the prior-year quarter. Total revenue decreased by 9% Y/Y, primarily due to lower grant revenue stemming from the completion of it's research grant from the California Institute for Regenerative Medicine, and an overall decrease in the sale of research products. Comment! [Healthcare, Earnings, On the Move]
Tuesday, March 19, 6:48 AM BioTime (BTX): Q4 EPS of -$0.12. Revenue of $1.2M (-30% Y/Y). (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, January 10, 4:04 PM BioTime (BTX +4%) finishes the day higher after saying earlier that it's submitted its Clinical Investigation Protocol to European regulators to begin clinical testing of its Renevia stem cell delivery platform. Comment! [Healthcare, On the Move, Global & FX]
Monday, January 7, 1:15 PM Shares of Geron (GERN +2.5%) snd BioTime (BTX +7.6%) both rise today after BTX agrees to buy the intellectual property, including patents and patent applications, and other assets related to GERN's human embryonic stem cell programs. The financial terms of the deal were in a letter of intent announced back in mid-November. Comment! [Healthcare, M&A, On the Move]
Tuesday, December 18, 2012, 9:58 AM BioTime (BTX +1.6%) has developed a method to produce seven distinct types of cartilage, bone, and tendon cells from human embryonic stem cells using the company's PureStem technology. A lab study showed that BioTime's cells, which can be manufactured on an industrial scale, are "progenitors to diverse skeletal tissues of the human body." BioTime expects to file a request for a Phase I trial in Q1. (PR) Comment! [Healthcare]
Friday, November 16, 2012, 8:24 AM Geron (GERN) +7.4% premarket after agreeing to sell its shuttered embryonic stem cell assets to BioTime (BTX), according to a non-binding letter of intent. The deal comes a year after GERN shut down the world's first trial of embryonic stem cells in humans. BTX says it arranged for a $10M investment from an undisclosed private investor to finance the proposed deal. Comment! [Healthcare, M&A, On the Move]
Friday, October 19, 2012, 12:23 PM Geron's (GERN -7.9%) board acknowledges receiving a letter from BioTime (BTX -3.3%) offering to buy its stem cell assets, saying it will review and act in a manner that it believes will be in the best interests of GERN's stockholders. The board adds that it's been considering a number of alternatives since its announcement earlier this month that it was discontinuing its stem cell research and development programs. Comment! [Healthcare, On the Move]
Thursday, October 18, 2012, 9:18 AM Geron (GERN) +5.8% premarket after BioTime (BTX) issues an open letter to GERN shareholders proposing a transaction between the two biopharma companies. Part of the proposal would allow GERN shareholders could own up to 45% of a new publicly traded company that would own GERN stem cell assets. 1 Comment [Healthcare, M&A, On the Move]
Thursday, August 16, 2012, 9:06 AM BioTime (BTX) and its OncoCyte unit publish a paper in which they identify the COL10A1 gene as a potential marker for numerous types of cancer. The upshot for BioTime is that the research should enhance PanC-DxTM, a low-cost device the company's developing to detect cancer using blood samples. (PR) Comment! [Healthcare]
Wednesday, April 11, 2012, 2:59 PM BioTime (BTX -9.3%) shares sink after a Seeking Alpha article by Martin Shkreli says the biotech smallcap is worth ~$20M vs. its current ~$221M market cap. "With only $22M in cash and limited operations... BioTime has a need for raising cash in the future... I predict BTX shares will drop at least 50% in the next 12 months." 2 Comments [Healthcare, On the Move]
Thursday, December 22, 2011, 10:21 AM Shares of BioTime (BTX -5.5%) slip on profit-taking following two-day rally after the firm disclosed (8-K) that it entered into two agreements with China-based USCN Life Science to license technology and patents, as well as purchase assets related to stem cell research. Comment! [On the Move, Healthcare]
Wednesday, December 21, 2011, 10:34 AM BioTime (BTX +4.8%) trades up after signing an agreement with USCN Life Science of Wuhan, China, to license its antibody-producing cell lines and related technology for use in the large-scale manufacture of antibody components for its cancer detection device, PanC-Dx. Comment! [Healthcare, On the Move, Global & FX]
Monday, December 19, 2011, 4:14 PM BioTime (BTX +1%) finishes the day in positive territory after WBB Securities upgraded the stock earlier today to Strong Buy, citing the potential of cancer detection device PanC-Dx. Comment! [Healthcare, On the Move]

BTX BioTime, Inc

BTX

BioTime, Inc